Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axicabtagene Ciloleucel + Rituximab in Refractory LBCL
NCT04002401Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Nov 2019
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Started Nov 2019; status: completed.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04002401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04002401.